指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

COPD基金会雾化器联盟关于降低雾化治疗中呼吸道感染传播风险的指导

Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer Consortium.
指南 / 共识 · Chest · 2023-11-15
一句话结论COPD基金会雾化器联盟发布专家指导,分别针对医疗机构和家庭环境提出降低雾化治疗中呼吸道感染传播风险的策略。

雾化器常用于吸入给药,但气溶胶生成引发感染传播安全性的担忧。COVID-19大流行凸显了理解气溶胶生成操作风险的重要性,然而支持雾化治疗增加疾病传播风险的证据尚不明确,指南不一致和意见分歧导致使用上的不确定性。COPD基金会雾化器联盟(CNC)于2020年成立,由患者倡导者、肺科医生、重症监护医生、呼吸治疗师、临床科学家和药师组成的国际多学科合作组织,通过文献和指南回顾制定了针对医疗机构和家庭环境的两套指导声明,以告知大流行期间或预期接触常见呼吸道病原体时雾化治疗的安全使用。未来研究需探索不同雾化器类型在真实患者护理中与逃逸气溶胶相关的疾病传播风险,并评估缓解策略的有效性。

要点

  • 雾化器通过气溶胶生成递送药物,在传染性呼吸道疾病设置中需明确安全气溶胶递送的定义。
  • 支持雾化治疗增加疾病传播风险的证据尚不明确,指南不一致和意见分歧导致使用不确定性。
  • 许多临床医生选择替代装置,但这一做法可能对患者结局产生负面影响,尤其是可能无法从手持吸入器获得完全治疗益处的患者。
  • COPD基金会雾化器联盟(CNC)于2020年成立,制定了针对医疗机构和家庭环境的两套指导声明。
  • 未来研究需探索不同雾化器类型在真实患者护理中与逃逸气溶胶相关的疾病传播风险,并评估缓解策略的有效性。

适用人群与场景

  • 接受雾化治疗的患者及提供治疗的医护人员,适用于大流行期间或预期接触常见呼吸道病原体时。

处置流程与药物剂量

  • CNC制定了针对医疗机构和家庭环境的两套指导声明,以告知雾化治疗的安全使用(具体推荐条款原文未列出)。

研究设计与关键结果

  • CNC成员回顾了关于雾化和指南的文献,制定了两套指导声明:一套用于医疗机构,一套用于家庭环境。

证据类型、等级与局限

  • 证据类型:专家指导(专家意见)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出具体推荐;作者认为未来研究需探索不同雾化器类型在真实患者护理中与逃逸气溶胶相关的疾病传播风险,并评估缓解策略的有效性。

指南或共识出处

  • COPD基金会雾化器联盟(CNC)专家指导,发表于Chest。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Nebulizers are used commonly for inhaled drug delivery. Because they deliver medication through aerosol generation, clarification is needed on what constitutes safe aerosol delivery in infectious respiratory disease settings. The COVID-19 pandemic highlighted the importance of understanding the safety and potential risks of aerosol-generating procedures. However, evidence supporting the increased risk of disease transmission with nebulized treatments is inconclusive, and inconsistent guidelines and differing opinions have left uncertainty regarding their use. Many clinicians opt for alternative devices, but this practice could impact outcomes negatively, especially for patients who may not derive full treatment benefit from handheld inhalers. Therefore, it is prudent to develop strategies that can be used during nebulized treatment to minimize the emission of fugitive aerosols, these comprising bioaerosols exhaled by infected individuals and medical aerosols generated by the device that also may be contaminated. This is particularly relevant for patient care in the context of a highly transmissible virus.

RESEARCH QUESTION: How can potential risks of infections during nebulization be mitigated?

STUDY DESIGN AND METHODS: The COPD Foundation Nebulizer Consortium (CNC) was formed in 2020 to address uncertainties surrounding administration of nebulized medication. The CNC is an international, multidisciplinary collaboration of patient advocates, pulmonary physicians, critical care physicians, respiratory therapists, clinical scientists, and pharmacists from research centers, medical centers, professional societies, industry, and government agencies. The CNC developed this expert guidance to inform the safe use of nebulized therapies for patients and providers and to answer key questions surrounding medication delivery with nebulizers during pandemics or when exposure to common respiratory pathogens is anticipated.

RESULTS: CNC members reviewed literature and guidelines regarding nebulization and developed two sets of guidance statements: one for the health care setting and one for the home environment.

INTERPRETATION: Future studies need to explore the risk of disease transmission with fugitive aerosols associated with different nebulizer types in real patient care situations and to evaluate the effectiveness of mitigation strategies.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Biney IN, Ari A, Barjaktarevic IZ, et al. Guidance on Mitigating the Risk of Transmitting Respiratory Infections During Nebulization by the COPD Foundation Nebulizer Consortium. Chest. 2023. PMID: 37977263. doi:10.1016/j.chest.2023.11.013

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。